Abstract Number: 1023 • 2016 ACR/ARHP Annual Meeting
Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
Background/Purpose: Romosozumab (Romo) is an investigational bone-forming monoclonal antibody that binds sclerostin and has a dual effect, increasing bone formation and decreasing bone resorption. Here,…Abstract Number: 1027 • 2016 ACR/ARHP Annual Meeting
Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial
Background/Purpose: Long-Term Odanacatib Fracture Trial [Women 65 years of age with BMD T-score ≤–2.5 at total hip (TH) or femoral neck (FN), or with radiographic…Abstract Number: 1028 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension
Background/Purpose: Denosumab (DMAb) treatment has been shown to decrease fracture (Fx) risk. Unlike bisphosphonates, DMAb is a monoclonal antibody against RANKL. Discontinuation is characterized by…Abstract Number: 1223 • 2016 ACR/ARHP Annual Meeting
The Cost of Confronting Osteoporosis:Cost Study of a Fracture Liaison Service
Background/Purpose: Services that actively seek out and identify patients with fractures following a minimal trauma injury have been promoted as the most effective means of…Abstract Number: 1232 • 2016 ACR/ARHP Annual Meeting
Interdisciplinary Osteoporosis Clinical Working Group and Fracture Liaison Service at Loma Linda University Medical Center (LLUMC): Laying the Groundwork
Background/Purpose: There is an ongoing effort worldwide to effect quality improvement to address secondary prevention of fractures. Patients who have incurred fractures attributed to osteoporosis…Abstract Number: 382 • 2015 ACR/ARHP Annual Meeting
Twelve Months after Osteoporosis Associated Fracture – Has Adequate Therapy Been Initiated?
Background/Purpose: Evidence shows that of ten patients taking medication against osteoporosis one will avoid subsequent fractures, decreasing the risk by > 50 %. On the…Abstract Number: 2084 • 2015 ACR/ARHP Annual Meeting
Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Modulates Bone Resorption in Inflammatory Arthritis and Fracture Repair
Background/Purpose: Osteoclasts (OC) direct pathologic bone resorption in osteoporosis and inflammatory arthritis. We previously demonstrated that DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a 7-pass transmembrane protein,…Abstract Number: 2165 • 2015 ACR/ARHP Annual Meeting
Awareness and Reasons for Lack of Post-Fracture Osteoporosis Therapy: A Survey of Post-Menopausal Women
Background/Purpose: Osteoporotic fractures cause patient morbidity and increase risk for future fracture. Effective drug therapies for osteoporosis (OP) are available, yet only a minority of…Abstract Number: 2210 • 2015 ACR/ARHP Annual Meeting
Immunological Dysregulation and Inadequate Hypoxia Adaptation – HIF-Stabilization As Possible Prevention of Fracture Healing Disorders in RA or Immune-Suppressed Patients
Background/Purpose: Patients suffering from rheumatoid arthritis (RA) are often affected by fracture-healing complications such as increased fracture healing time or non-unions. There is not much…Abstract Number: 3173 • 2015 ACR/ARHP Annual Meeting
Premature Mortality Due to Fractures in a Population-Based Prospective Cohort Study of 238,673 Older Women and Men
Background/Purpose: Osteoporotic (OP) fractures and falls are a growing global problem as the population ages. One third of all falls related deaths are attributable to…Abstract Number: 346 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis. However the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a bone protective protein that acts as…Abstract Number: 371 • 2015 ACR/ARHP Annual Meeting
New Vertebral Fractures after Vertebroplasty: Two Year Results from a Randomised Placebo-Controlled Trial
Background/Purpose: We previously reported the results of a randomized participant and outcome assessor blinded controlled trial that found no beneficial effect of vertebroplasty (VP) over…Abstract Number: 2471 • 2014 ACR/ARHP Annual Meeting
Effect of Teriparatide in Patients with Osteoporosis and Rheumatoid Arthritis
Background/Purpose: A common complication in rheumatoid arthritis (RA) is osteoporosis (OP) with increased incidence of fragility fractures. RA is the only disease specifically included…Abstract Number: 2268 • 2014 ACR/ARHP Annual Meeting
Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial
Background/Purpose: Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. The Phase III Long-Term Odanacatib Fracture Trial…Abstract Number: 2106 • 2014 ACR/ARHP Annual Meeting
Surgical Compared with Nonsurgical Management of Fractures in Men with Chronic Spinal Cord Injury
Background/Purpose: Patients with a chronic spinal cord injury (SCI) develop osteoporosis and are at high risk for fracture. However, there is limited information on how…